Making it in Manufacturing

ARTO Talent
  • 0.0 (0)
  • PROFESIONES
  • CADA SEMANA

97% of our listeners don't realise they aren't followed, please double check, thank you! Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series, spotlighting the leaders shaping the future of manufacturing, engineering and CDMOs in Life Sciences. Each episode dives into the careers, decisions, and defining moments of industry mainstays - revealing the stories and insights behind real-world impact within the life science manufacturing and CDMO space. If you're a leader in the space - or aspiring to be - this podcast is a must watch. The series is available on YouTube, Spotify, Apple Podcasts and all major platforms. Hosted on Acast. See acast.com/privacy for more information.

  1. Inside Mabion’s Growth Strategy | CEO Gregor Kawaletz on Biosimilars & Biologics

    HACE 12 H

    Inside Mabion’s Growth Strategy | CEO Gregor Kawaletz on Biosimilars & Biologics

    What does it take to step into a publicly listed CDMO and immediately reposition it for growth in a shifting global market? At Mabion, it starts with people, scientific excellence and a clear commercial vision. This week on Making It In Manufacturing, Thomas McMann sat down with Gregor Kawaletz, CEO of Mabion, bringing over 20 years of experience in the CDMO space spanning leadership roles across NextPharma, Catalent and Recipharm. Now in the first month as CEO, Gregor shares why this move was about broader impact and how the organisation will be steered into its next phase. In this episode, Gregor covers: • The first month as CEO at @Mabion and why “every company is about people” • The transition from Chief Commercial Officer roles into a CEO position with responsibility for the full organisation • Growth priorities, pipeline confidence and an upcoming adjusted business model • The €500,000 innovation initiative and awarding @WPD for novel antibody drug conjugate programmes in oncology • Regulatory shifts in the biosimilar space and how reduced requirements are expanding patient access The conversation also explores operating in a more multipolar global environment and why CDMOs must move beyond traditional fee-for-service models toward deeper collaboration and network thinking. For professionals in biologics, biosimilars or CDMO partnerships, this episode offers strategic insight shaped by experience across NextPharma, Catalent, Recipharm and now at Mabion. Check out this episode to hear how scientific depth, commercial leadership and organisational alignment can reposition a CDMO for long-term success. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@life_sciences Gregor Kawaletz - CEO at Mabion LinkedIn: https://www.linkedin.com/in/gregor-kawaletz-276a4830/ Thomas McMann - Director At ARTO LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 00:00 First month as CEO at Mabion 02:19 Two decades in the CDMO space including NextPharma, Catalent and Recipharm 02:42 Moving from CCO to CEO 05:10 Growth strategy and business model evolution 06:57 €500k innovation award and WPD 09:41 Biosimilars regulation and market access 11:04 Navigating a multipolar global supply landscape 12:47 Expanding Mabion’s future offering #MakingItInManufacturing #ARTOTalent #CDMO #Biologics #Biosimilars #LifeSciences #ManufacturingLeadership Hosted on Acast. See acast.com/privacy for more information.

    14 min
  2. Building Trust in Pharma and Biotech Manufacturing Partnerships | Sharp Services

    29 ENE

    Building Trust in Pharma and Biotech Manufacturing Partnerships | Sharp Services

    What does it really take to build trust in pharmaceutical and biotech partnerships when timelines are tight, expectations are high, and the market never stands still? This week on Making It In Manufacturing, Tom McMann sat down with Alexander Schäfer, Business Development Manager, to unpack what strong execution, honest communication, and long-term thinking look like inside global contract packaging services. In this episode, Alexander shares insights from his work across European operations in pharmaceutical and biotech packaging, supporting everyone from early-stage virtual biotechs to established blue-chip pharma organisations. Speaking from the floor of CPHI, one of the industry’s most important global events, he breaks down how expectations shift across company sizes and why trust is earned through delivery, not promises. Throughout the conversation, Alexander references the realities of operating at scale within global packaging services, the importance of listening to market demand, and how investment decisions are shaped by customer needs and long-term industry trends. In this episode, Alexander Schäfer covers: • How servicing small biotechs versus large pharma companies requires different approaches to expectations and support (01:28) • Why trust in business development is built through execution, consistency, and reputation over time (03:12) • The importance of open communication and solution-led thinking when projects face challenges (04:24) • What skills matter most in business development, including listening, asking the right questions, and understanding customer pain points (06:29) • How major investments into packaging capacity, injectables, and device assembly are shaping the future of the industry (07:21) This conversation was recorded during CPHI, where industry leaders come together to discuss innovation, investment, and the future of pharmaceutical manufacturing. It offers a grounded look at how business development works behind the scenes in a highly regulated, fast-moving environment. If you are working in pharma, biotech, manufacturing, or commercial leadership, this episode offers practical insight into how long-term partnerships are built and sustained. Check out the full episode now. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ YouTube: https://www.youtube.com/@life_sciences Alexander Schäfer LinkedIn: https://www.linkedin.com/in/alexander-sch%C3%A4fer-4515a433/ Tom McMann LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 00:00 Introduction and context from CPHI 00:54 Overview of European operations and contract packaging services 01:28 Servicing biotech versus pharma clients 03:12 Building trust through execution and reputation 04:24 Managing challenges with open communication and solutions 06:29 Essential skills for business development professionals 07:21 Investment in injectables, devices, and future capacity 10:25 Closing reflections #MakingItInManufacturing #ARTOTalent #PharmaManufacturing #Biotech #BusinessDevelopment #CPHI #ContractPackaging Hosted on Acast. See acast.com/privacy for more information.

    10 min
  3. What Makes a CDMO Investable? Ankit Gupta on Building Instapill for Long-Term Growth

    16 ENE

    What Makes a CDMO Investable? Ankit Gupta on Building Instapill for Long-Term Growth

    The CDMO Changing the Game in Drug Delivery This week, in another episode of the Making it in Manufacturing Spotlight Series, we sit down with Ankit Gupta, CEO of Instapill, a company redefining oral drug delivery through freeze-dried, fast-dissolving tablets. With over 15 years of experience spanning investment banking, M&A, and leadership roles in pharmaceutical manufacturing, Ankit brings a sharp perspective on scaling, innovation, and sustainable differentiation. In this episode, Ankit covers: Instapill’s unique FDA-approved non-gelatin ODT technology and why it’s transforming patient outcomes in paediatrics and geriatrics.Scaling up manufacturing capacity in India and future expansion plans into the US, and how automation will maintain quality at scale.How digital transformation and AI are shaping pharmaceutical manufacturing, from paperless R&D to data-driven precision in production.What makes a CDMO attractive to investors, and how sustainable differentiation trumps trend-driven momentum.Lessons from M&A and investment banking, and how they inform his approach as a CEO leading growth in a competitive CDMO landscape. Be sure to check out this episode to hear how Instapill is not only innovating formulation, but reimagining the future of pharma manufacturing. To listen to (or watch) the full episode, search "Making it in Manufacturing Instapill" on your preferred streaming platform. Or, click on the first link in the comments below. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/0kEcRZO... Instagram: https://www.instagram.com/arto.talent... TikTok: https://www.tiktok.com/@artotalent?_t... Apple Podcasts: https://podcasts.apple.com/us/podcast... Website: https://arto-talent.com Youtube: https://www.youtube.com/@life_sciences Ankit Gupta CEO at Instapill LinkedIn: https://www.linkedin.com/in/reachankit/ Thomas McMann Director - Contracts Division LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 00:11 Stand Out FDA Approval & Speed to Market 08:00 Global Growth and Operations 10:55 Insights & Leadership Takeaways Hosted on Acast. See acast.com/privacy for more information.

    14 min
  4. Redefining Biomanufacturing: Himanshu Gadgil on Enzene’s Global CDMO Expansion

    5 ENE

    Redefining Biomanufacturing: Himanshu Gadgil on Enzene’s Global CDMO Expansion

    Continuous manufacturing is reshaping biologics - and today’s guest is one of the leaders driving that shift. This week, in another episode of the Making It in Manufacturing Spotlight Series, we sit down with Himanshu Gadgil, PhD, CEO of Enzene. With over a decade of experience spanning scientific innovation, biologics development & manufacturing, global expansion and CDMO leadership, Himanshu shares the story behind Enzene’s rise from a small R&D biotech in India to a rapidly scaling global CIDMO with newly established US manufacturing. In this episode, Himanshu covers: - How Enzene built and evolved its first-in-class, fully-connected continuous manufacturing platform, EnzeneX - including initial failures shaped breakthrough innovation. - Why fully-connected continuous manufacturing™ is a cost and efficiency game-changer for biologics. - The regulatory and operational challenges of scaling this technology - and how Enzene approached India-to-US expansion. - Leadership lessons in his progression from scientist to CEO, including culture, resilience, and recognising that success depends on the combination of transformative innovation with a unique values/mission-driven approach to the way business gets done. - The future of biomanufacturing - from localisation and personalised production to fully automated, analytics-driven systems. Be sure to check out this episode to hear how Enzene is redefining what a modern CDMO can be. To listen to (or watch) the full episode, search "Making it in Manufacturing Enzene" on your preferred streaming platform, or click on the first link in the comments below. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com Youtube: https://www.youtube.com/@life_sciences Himanshu Gadgil CEO of Enzene LinkedIn: https://www.linkedin.com/in/himanshu-gadgil-3326307/ Thomas McMann Director - Contracts Division LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 00:10 Enzene's Vision 04:10 Building & Scaling a Global Platform 07:51 Enzene's Competitive Edge 14:56 The Future of CDMO's 21:01 Vision for Enzene's Future Growth Hosted on Acast. See acast.com/privacy for more information.

    22 min
  5. Scaling a Legacy CDMO: Inside Pyramid Pharma’s Fill-Finish Expansion

    23/12/2025

    Scaling a Legacy CDMO: Inside Pyramid Pharma’s Fill-Finish Expansion

    The CDMO everyone’s suddenly talking about, and the CEO taking it to the next level. This week, in another episode of the Making It in Manufacturing Spotlight Series, hosted by Thomas McMann, we sit down with Dirk T. Lange, CEO at Pyramid Pharma Services. With 30 years of experience across drug-substance and drug-product CDMOs, global operations, outsourcing leadership, and life-science services, spanning Rentschler, KBI Biopharma, Novartis, Sandoz, and more, Dirk brings a rare dual-lens perspective from both the provider and sponsor side. In this episode, Dirk covers: - A full overview of Pyramid Pharma Services, a 37-year-old CDMO with an exceptionally broad drug-product offering from clinical to commercial supply. - Key data behind Pyramid’s under-the-radar growth, including 15 successful FDA inspections, a strong legacy of quality, and decades of organic expansion driven by long-term customer partnerships. - Why they’re doubling their fill–finish capabilities, including the strategic drivers, client demand, and the transition from clinical-scale to high-speed commercial lines. - The operational realities of scaling, from maintaining culture to onboarding new teams, strengthening processes, and preserving execution excellence during rapid growth. - How Pyramid positions itself as an enabler in the supply chain, supporting customers from early development through long-term commercial supply. Be sure to check out this episode, a deep dive into what it really takes to scale a legacy CDMO while protecting quality, culture, and customer trust. To listen to (or watch) the full episode, search "Making it in Manufacturing Pyramid Pharma" on your preferred streaming platform, or click on the first link in the comments below. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com Youtube: https://www.youtube.com/@life_sciences Dirk T. Lange CEO at Pyramid Pharma Services LinkedIn: https://www.linkedin.com/in/langedirk/ Thomas McMann Director - Contracts Division LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 00:11 Pyramid Overview 01:41 Key Data 03:46 Doubling Fill Finish Capabilities 05:38 Growth Challenges Hosted on Acast. See acast.com/privacy for more information.

    8 min
  6. $45M Expansion: What’s Next for Argonaut’s Aseptic Manufacturing Capabilities

    16/12/2025

    $45M Expansion: What’s Next for Argonaut’s Aseptic Manufacturing Capabilities

    In this episode of the Making It in Manufacturing Spotlight Series, we sit down with Raj Puri, Chief Commercial Officer at Argonaut Manufacturing Services. With over 12 months in the CCO role and extensive experience across the CDMO space, Raj brings insight from leading business development, project management, and commercial strategy across both life science/diagnostics and aseptic drug-product services. In this episode, Raj covers: - Why Argonaut chooses to support “N of 1” programmes, and the cultural impact of delivering life-saving therapies for single-patient treatments. - The operational challenges of ultra-high-value API filling, and how Argonaut minimises line losses for rare-disease therapies. - The company’s evolution, from diagnostics to becoming a major player in small- to mid-scale aseptic drug-product manufacturing. - How Argonaut’s new $45M facility and commercial-scale filling line will transform output, enable prefilled syringes/cartridges, and support global demand. - The realities of scaling a CDMO, including hiring, maintaining culture, preparing for FDA pre-approval inspection, and setting long-term strategy for future capabilities. Be sure to check out this episode to hear Raj’s candid take on growth, culture, and the future of drug-product manufacturing. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com Youtube: https://www.youtube.com/@life_sciences Raj Puri CCO at Argonaut Manufacturing Services LinkedIn: https://www.linkedin.com/in/raj-puri-3137665/ Thomas McMann Director - Contracts Division at ARTO LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 00:10 Stepping Into The Role & Early Lessons 04:03 Scaling Smart: Challenges and Capabilities 09:07 Culture, Talent & The Future Hosted on Acast. See acast.com/privacy for more information.

    14 min
  7. The CDMO Changing Oral Drug Delivery – Instapill CEO Ankit Gupta

    15/12/2025

    The CDMO Changing Oral Drug Delivery – Instapill CEO Ankit Gupta

    The CDMO Changing the Game in Drug Delivery This week, in another episode of the Making it in Manufacturing Spotlight Series, we sit down with Ankit Gupta, CEO of Instapill, a company redefining oral drug delivery through freeze-dried, fast-dissolving tablets. With over 15 years of experience spanning investment banking, M&A, and leadership roles in pharmaceutical manufacturing, Ankit brings a sharp perspective on scaling, innovation, and sustainable differentiation. In this episode, Ankit covers: - Instapill’s unique FDA-approved non-gelatin ODT technology and why it’s transforming patient outcomes in paediatrics and geriatrics. - Scaling up manufacturing capacity in India and future expansion plans into the US, and how automation will maintain quality at scale. - How digital transformation and AI are shaping pharmaceutical manufacturing, from paperless R&D to data-driven precision in production. - What makes a CDMO attractive to investors, and how sustainable differentiation trumps trend-driven momentum. - Lessons from M&A and investment banking, and how they inform his approach as a CEO leading growth in a competitive CDMO landscape. Be sure to check out this episode to hear how Instapill is not only innovating formulation, but reimagining the future of pharma manufacturing. To listen to (or watch) the full episode, search "Making it in Manufacturing Instapill" on your preferred streaming platform. Or, click on the first link in the comments below. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com Youtube: https://www.youtube.com/@life_sciences Ankit Gupta CEO at Instapill LinkedIn: https://www.linkedin.com/in/reachankit/ Thomas McMann Director - Contracts Division LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 00:11 Stand Out FDA Approval & Speed to Market 08:00 Global Growth and Operations 10:55 Insights & Leadership Takeaways Hosted on Acast. See acast.com/privacy for more information.

    14 min
  8. How ten23 Became One of Europe’s Fastest-Growing Drug-Product CDMOs

    11/12/2025

    How ten23 Became One of Europe’s Fastest-Growing Drug-Product CDMOs

    What does it really take to build one of Europe’s fastest-growing drug-product CDMOs, and do it with scientific precision, culture-first leadership, and a B-Corp mindset? This week, in another episode of the Making It in Manufacturing Spotlight Series, we sit down with Hanns-Christian Mahler, CEO & Founder of ten23. With over 20 years of experience spanning senior roles at Merck, Roche, biopharma development, drug-product strategy, and CDMO leadership, Hanns-Christian brings a rare blend of scientific rigour, sustainability vision, and people-centric leadership. In this episode, Hanns-Christian covers: - The origin story of ten23 and why he left big pharma to challenge the CDMO status quo with ten23 - Why ten23 leads with partnership - not execution - and how “asking better questions” is their competitive edge ten23 - ten23’s rapid growth journey: new filling lines, site expansion, headcount growth, and strategic partnerships, like with BD - The culture behind the company: transparency, autonomy, values-led leadership, and building a truly learning organisation at ten23 - The future of CDMOs: AI adoption with intention, sustainability as a scientific discipline, and what’s next for ten23’s global footprint - Hanns-Christian also speaks about his partnerships with sustainability-focused companies such as Lio, led by CEO Vladimir Keil, highlighting how these collaborations help drive more responsible and efficient operations. If you want a masterclass in modern CDMO leadership, rooted in science, innovation, and purpose, this is the episode to watch. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com Youtube: https://www.youtube.com/@life_sciences Hanns-Christian Mahler CEO at ten23 LinkedIn: https://www.linkedin.com/in/hanns-christian-mahler/ Thomas McMann Director - Contracts Division at ARTO LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 00:00 Career Beginnings & ten23 08:18 Challenges with Scaling 14:29 Culture & Leadership Style 20:00 Scientific Rigour vs Sustainability 26:07 Challenges with Geopolitical Issues 29:13 The Future & AI Hosted on Acast. See acast.com/privacy for more information.

    39 min
Ver todo (15)

Acerca de

97% of our listeners don't realise they aren't followed, please double check, thank you! Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series, spotlighting the leaders shaping the future of manufacturing, engineering and CDMOs in Life Sciences. Each episode dives into the careers, decisions, and defining moments of industry mainstays - revealing the stories and insights behind real-world impact within the life science manufacturing and CDMO space. If you're a leader in the space - or aspiring to be - this podcast is a must watch. The series is available on YouTube, Spotify, Apple Podcasts and all major platforms. Hosted on Acast. See acast.com/privacy for more information.

Información

  • Creador
    ARTO Talent
  • Años de actividad
    2025 - 2026
  • Episodios
    15
  • Clasificación
    Apto
  • Copyright
    © ARTO Talent
  • Mostrar sitio web
    Making it in Manufacturing